搞经济 抄底 加仓 :
I though I got the dip , till news out that ARK came on board. I know this is not the end.. Average Down^together 还以为抄底了 知道木头也买了。。那一瞬间我知道那不是低点了。。。哇c
$Veracyte(VCYT.US)$ Veracyte announced that it has begun rolling out its long-awaited nasal swab test for lung cancer at a limited number of clinical sites, as the company continues to accumulate data to support its future full commercial rollout. The company also published recent findings showing that the Percepta Genomic test can more accurately group patients based on their risk of developing tumors and suspicious lung nodules.
Veracyte股票讨论
选择效仿 ESMO 的生物技术/制药公司名称:
$Clovis Oncology(CLVS.US)$ +11.3%, $Cardiff Oncology(CRDF.US)$ +9%, $Immatics(IMTX.US)$ +8.3%, $IDEAYA生物科学(IDYA.US)$ +8%, $Lyra Therapeutics(LYRA.US)$ +5.7%, $POINT Biopharma(PNT.US)$ +5.7%, $Edgewise Therapeutics(EWTX.US)$ +4.7%, $Concert Pharmaceuticals(CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US)$ +3.2%, $Veracyte(VCYT.US)$ +2.6%, $SpringWorks Therapeutics(SWTX.US)$ +2.3%,...
• $Theravance Biopharma(TBPH.US)$ +15.9%(TBPH将以超过15亿美元的价格将其在Theravance Resiration的所有单位出售给RPRX)
• $Amryt Pharma(AMYT.US)$ +11.9%(美国食品药品管理局授予 Mycapsa 孤儿药称号,用于治疗类癌综合症)
• $Green Brick Partners(GRBK.US)$ +7.3%(加入标普小型股 600)
• $TransGlobe Energy(TGA.US)$ +6.9%(Transglobe Energy 将被VALLCO Energy(EGY)以股票换股票收购...
• $Microvast(MVST.US)$ +14.6%(对收益的反应)
• $Sea(SE.US)$ +11.3%(第一季度调整后亏损扩大,收入增长)
• $京东(JD.US)$ +9.1%(超过了最近一个季度的收入和利润预期)
• $Coinbase(COIN.US)$ +6.3%(宣布 “正在放慢招聘速度,以便我们可以根据最优先的业务目标调整招聘需求的优先级”)
• $Heliogen(HLGN.US)$ +5%(用于重申 2021 年全年财务状况)
• $Take-Two互动软件(TTWO.US)$ +4.9%(德国...
• $Affirm Holdings(AFRM.US)$ +36.4%(还宣布将与美国SHOP的独家合作伙伴关系延长多年)
• $Robinhood(HOOD.US)$ +22.9%(新兴富达披露7.6%的股份;加密货币交易所FTX首席执行官山姆·班克曼-弗里德是基金的多数股东)
• $奋进集团(EDR.US)$ +20%(对收益的反应)
• $Coinbase(COIN.US)$ +13%(与胡德新闻同情)
• $德纳维制药(DVAX.US)$ +11.5%(加入...
ARK 的收购
$Robinhood(HOOD.US)$ $Nu Holdings(NU.US)$ $Veracyte(VCYT.US)$ $Personalis(PSNL.US)$ $PagerDuty(PD.US)$ $Quantum-Si(QSI.US)$
ARK's 的销量
$Iovance Biotherapeutics(IOVA.US)$ $LivePerson(LPSN.US)$ $3D系统(DDD.US)$
Veracyte announced that it has begun rolling out its long-awaited nasal swab test for lung cancer at a limited number of clinical sites, as the company continues to accumulate data to support its future full commercial rollout.
The company also published recent findings showing that the Percepta Genomic test can more accurately group patients based on their risk of developing tumors and suspicious lung nodules.
暂无评论